Kozak-Szkopek E
Katedry i Kliniki Chorób Wewnetrznych, Akademii Medycznej w Lublinie.
Pneumonol Alergol Pol. 1995;63(9-10):532-8.
The aim of the study was to carry out assessment of the respiratory function of patients with COPD undergoing a three month (600 microgram) treatment with an inhaled steroid--Budesonide. This was a double blind study carried out on 57 patients. During treatment with Budesonide a clinical improvement was seen. Respiratory function parameters did not alter throughout the 3 month treatment period, although bronchial reactivity diminished. Side effects were seen only in 3 patients--in all it was dysphonia. It seems that Budesonide can be added to other treatment protocols in patients with exacerbations of chronic bronchitis.
该研究的目的是对慢性阻塞性肺疾病（COPD）患者进行为期三个月（600微克）的吸入性类固醇药物——布地奈德治疗后的呼吸功能进行评估。这是一项对57名患者进行的双盲研究。在使用布地奈德治疗期间，观察到临床症状有所改善。尽管支气管反应性降低，但在整个3个月的治疗期间呼吸功能参数并未改变。仅3名患者出现了副作用——均为声音嘶哑。似乎布地奈德可添加到慢性支气管炎急性加重患者的其他治疗方案中。
